Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterized by the thickening and stiffening of lung tissue, which makes it increasingly difficult to breathe over time.
Lung Fibrosis: ENV-101 Treatment Study
We are testing a new medication, ENV-101, for people with lung fibrosis to see if it improves lung function and overall health. The study will also look at the safety of this treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 40 years old or older?
- Do you have a diagnosis of idiopathic pulmonary fibrosis (IPF) confirmed by a doctor within the last 5 years?
- Have you had a lung function test that shows your percent predicted FVC is 45% or higher?
- Have you had stable treatment for IPF with antifibrotics for at least 3 months before the study starts, or have you not been treated for at least 8 weeks before the study starts?
- Have you had an acute worsening of your IPF in the last 3 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Taladegib
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical University Of Graz
#158: Universitätsklinik, für Innere Medizin, Klinische Abteilung für Pulmonologie
Graz, Austria
Medical University Of Vienna
#120: Klinische Abteilung für Pulmologie
Vienna, Austria
Hopital Erasme
#161: Gastroenterologie-oncologie
Negenmanneke, Belgium
Sponsor: Endeavor Biomedicines Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.